This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Hologic Q2 Earnings & Revenues Top, '25 EPS View Lowered, Stock Down
by Zacks Equity Research
HOLX delivers earnings and revenue beat in the second quarter of fiscal 2025 amid macroeconomic turbulence.
IDXX Q1 Earnings Beat, FY25 View Raised, Stock Up in Pre-Market
by Zacks Equity Research
IDEXX delivers year-over-year earnings and revenue growth in the first quarter of 2025.
ICON's Q1 Earnings Surpass Estimates, Revenues Lag, Stock Down
by Zacks Equity Research
ICLR posts mixed results in the first quarter of 2025 due to ongoing clinical development and market volatility.
CVS Q1 Earnings & Revenues Beat, '25 EPS View Raised, Stock Up
by Zacks Equity Research
CVS Health delivers earnings and revenue beat in the first quarter of 2025.
ALGN Q1 Earnings and Revenues Top Estimates, Stock Up in After-market
by Zacks Equity Research
Align Technology reports first-quarter 2025 financial results, reflecting strength in the Imaging Systems & CAD/CAM Services business segment.
Labcorp Q1 Earnings Surpass Estimates, Revenues Miss, Stock Gains
by Zacks Equity Research
LH delivers better-than-expected earnings in the first quarter of 2025.
Wall Street Analysts See a 63.23% Upside in AngioDynamics (ANGO): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 63.2% in AngioDynamics (ANGO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Is Astellas Pharma (ALPMY) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Astellas Pharma Inc. (ALPMY) and AngioDynamics (ANGO) have performed compared to their sector so far this year.
CHE Stock Falls Despite Q1 Earnings & Revenue Beat, Gross Margin Declines
by Zacks Equity Research
Chemed delivers first-quarter top-line growth across two of its segments, VITAS and Roto-Rooter.
Penumbra Q1 Earnings & Revenues Top Estimates, Stock Up, Margins Expand
by Zacks Equity Research
PEN reports better-than-expected earnings and revenues in the first quarter of 2025.
AMED Stock Trades Flat Despite Q1 Earnings Beat, Margins Rise
by Zacks Equity Research
Amedisys delivers first-quarter top-line growth across three of its segments, namely Home Health, Hospice and High Acuity Care.
ResMed Q3 Earnings and Revenues Beat, Stock Up in After-Market
by Zacks Equity Research
RMD's stellar third-quarter fiscal 2025 results reflect the ongoing momentum and strong execution across all areas of its business.
EW Q1 Earnings & Revenues Beat, Stock Climbs, '25 Sales View Raised
by Zacks Equity Research
Edwards Lifesciences' first-quarter 2025 performance benefits from its differentiated portfolio of therapies to treat patients with structural heart disease.
Thermo Fisher's Q1 Earnings Top Estimates, Revenues Beat, Stock Up
by Zacks Equity Research
TMO continues to advance its growth strategy and trusted partner status with customers in the first quarter of 2025.
BSX Q1 Earnings & Revenues Beat, Stock Up, 2025 View Raised
by Zacks Equity Research
Boston Scientific's first-quarter 2025 performance benefits from the strength of its product portfolio.
Concentra Stock Slips Despite Deal to Acquire Pivot Onsite Innovations
by Zacks Equity Research
CON is set to acquire Pivot Onsite Innovations, expanding its onsite occupational health services and strengthening its national footprint in workforce health solutions.
Quest Diagnostics Q1 Earnings & Revenues Top Estimates, Stock Up
by Zacks Equity Research
DGX delivers solid top-line growth in the first quarter of 2025.
ECL Stock Gains Following 5% Trade Surcharge in the United States
by Zacks Equity Research
Ecolab announces a 5% U.S. trade surcharge to offset rising costs.
Abbott Q1 Earnings Beat, Sales Miss, Stock Falls in Pre-Market
by Zacks Equity Research
ABT delivers a strong underlying base business performance for the first quarter of 2025.
CBLL Stock Falls Despite FDA Clearance for Pediatric Clarity Algorithm
by Zacks Equity Research
Ceribell secures FDA clearance for Clarity algorithm in pediatric patients, expanding rapid seizure detection capabilities and enhancing critical care efficiency.
Reasons to Retain DENTSPLY SIRONA Stock in Your Portfolio Now
by Zacks Equity Research
XRAY continues to gain traction from a robust product portfolio. However, the macroeconomic factors, such as weakened global demand, persist.
LFWD Stock Falls Despite Launch of Next-Generation Mobility ReWalk 7
by Zacks Equity Research
Lifeward launches ReWalk 7 in the United States, offering advanced mobility, greater control and smarter walking for individuals with spinal cord injuries.
Here's Why You Should Retain Inogen Stock in Your Portfolio Now
by Zacks Equity Research
Expanding product portfolio and high prospects for POC raise optimism for INGN stock.
HealthEquity Stock Plunges 13% YTD: Is It Time to Exit or Hold?
by Zacks Equity Research
HQY stock is down more than 13% YTD amid cyber threats and rising costs, but strong HSA fundamentals remain. Is it time to hold or fold? Let's break it down.
Merit Medical Stock Slips Despite the Launch of New Ventrax System
by Zacks Equity Research
MMSI launches the Ventrax Delivery System, enhancing pulmonary access procedures with improved control, precision, and efficiency for interventionalists.